RxDoctor Payments Data

Won Kim, MD

Internal Medicine · Philadelphia, PANPI 1437199502

Payments from drug & device makers

$3,904in general payments, 2019–2025

Across 179 payments — averaging $21.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$1K
  • Novo Nordisk$983
  • Gilead$855
  • Sumitomo Pharma America, Inc.$205
  • Astellas Pharma US Inc$193
  • Kowa Pharmaceuticals America, Inc.$141
  • plus $437 from 12 others

What the payments were for

  • Food & beverage$3,904100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,904 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$21,993
Medicare patients
67
Services billed
336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin313$290,957
VascepaIcosapent Ethyl278$194,642
JanuviaSitagliptin Phosphate190$170,014
EliquisApixaban138$122,082
OzempicSemaglutide93$94,758
Icosapent Ethyl187$60,366
VemlidyTenofovir Alafenamide39$57,407
RybelsusSemaglutide48$48,663
MyrbetriqMirabegron91$44,907
FarxigaDapagliflozin Propanediol42$29,479
Tenofovir Disoproxil Fumarate38$26,549
GemtesaVibegron34$15,763
Fluticasone-SalmeterolFluticasone Propion/Salmeterol65$13,696
XareltoRivaroxaban13$11,153
Atorvastatin Calcium960$11,076

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$983$143,421141 claims
PfizerEliquis$30$122,082138 claims
GileadVemlidy$855$57,40739 claims
Astellas Pharma US IncMyrbetriq$193$44,90791 claims
AstraZenecaFarxiga$18$29,47942 claims
Sumitomo Pharma America, Inc.Gemtesa$205$15,76334 claims
Johnson & JohnsonXarelto$15$11,15313 claims
GSKBreo Ellipta$20$10,72323 claims
BayerKerendia$23$7,09712 claims
AbbVieNamzaric$74$6,96912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →